Shares of Aurinia Pharmaceuticals Inc. (TSE:AUP – Get Free Report) (NASDAQ:AUPH) fell 3.5% during trading on Monday . The stock traded as low as C$16.41 and last traded at C$16.76. 4,611,683 shares changed hands during trading, an increase of 1,906% from the average session volume of 229,895 shares. The stock had previously closed at C$17.37.
Aurinia Pharmaceuticals Trading Down 3.5 %
The stock has a market cap of C$2.15 billion and a P/E ratio of -11.32. The company has a debt-to-equity ratio of 2.69, a current ratio of 11.93 and a quick ratio of 11.02. The business has a fifty day moving average of C$16.76.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Articles
- Five stocks we like better than Aurinia Pharmaceuticals
- Which Wall Street Analysts are the Most Accurate?
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Bank Stocks – Best Bank Stocks to Invest In
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
